PBH Share Price | Prestige Consumer Healthcare, Inc. Stock Analysis & Recommendation

Q: How big is Prestige Consumer Healthcare, Inc.?

Market Cap: As of Jun 18, Prestige Consumer Healthcare, Inc. has a market capitalization of 4,482.38 million, classifying it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 1,137.77 million and a net profit of 214.61 million.Balance Sheet Snapshot: As of Mar 25, the company has shareholder's funds amounting to 1,834.90 million and total assets of 3,455.49 million.

Q: What does Prestige Consumer Healthcare, Inc. do?

Overview:Prestige Consumer Healthcare, Inc. is engaged in the marketing, sales, and distribution of over-the-counter healthcare products within the Pharmaceuticals & Biotechnology industry and operates in the small-cap market.Financial Snapshot:- Net Sales: 297 Million (Quarterly Results - Mar 2025)- Net Profit: 50 Million (Quarterly Results - Mar 2025)- Market cap: USD 4,482.38 Million (Small Cap)Key Metrics:- P/E: 20.00- Dividend Yield: 0.00%- Debt Equity: 0.49- Return on Equity: 12.16%- Price to Book: 2.44Contact Details:- Address: 660 White Plains Rd, TARRYTOWN NY: 10591-5139- Tel: 1 914 5246800- Website: http://prestigebrands.com

Q: Is Prestige Consumer Healthcare, Inc. technically bullish or bearish?

As of 31 July 2025, the technical trend for Prestige Consumer Healthcare, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the weekly MACD and moving averages, both showing bearish signals. The Bollinger Bands and KST also reflect a bearish trend on the weekly timeframe. The Dow Theory supports a mildly bearish outlook on both weekly and monthly periods. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -17.92% compared to the S&P 500's 12.22%, and a one-year return of -12.82% versus the S&P 500's 17.14%.

Q: Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. The company appears to be overvalued based on its current metrics, with a P/E ratio of 20, a Price to Book Value of 2.48, and an EV to EBITDA ratio of 14.39, all of which are higher than those of its peers. For instance, Alkermes Plc has a P/E of 13.77 and an EV to EBITDA of 9.41, suggesting that Prestige is trading at a premium compared to its industry counterparts.The company's recent performance shows a stark contrast to the broader market, with a year-to-date return of -20.49% compared to the S&P 500's gain of 13.30%. This underperformance, along with the high valuation ratios, reinforces the conclusion that Prestige Consumer Healthcare, Inc. is currently overvalued.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

390.98 k

Shareholding (Dec 2025)

FII

9.47%

Held by 118 FIIs

DII

30.12%

Held by 68 DIIs

Promoter

0.13%

How big is Prestige Consumer Healthcare, Inc.?

22-Jun-2025

As of Jun 18, Prestige Consumer Healthcare, Inc. has a market capitalization of $4.48 billion, with net sales of $1.14 billion and a net profit of $214.61 million over the latest four quarters.

View full answer

What does Prestige Consumer Healthcare, Inc. do?

22-Jun-2025

Prestige Consumer Healthcare, Inc. markets and distributes over-the-counter healthcare products and operates in the small-cap Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $297 million and a net profit of $50 million, with a market cap of approximately $4.48 billion.

View full answer

Who are in the management team of Prestige Consumer Healthcare, Inc.?

22-Jun-2025

As of March 2022, the management team of Prestige Consumer Healthcare, Inc. includes Mr. Ronald Lombardi as Chairman, President, and CEO, with Dr. Gary Costley as Lead Independent Director and several Independent Directors: Mr. John Byom, Mr. Christopher Coughlin, Ms. Sheila Hopkins, and Mr. James Jenness. They oversee the company's operations and strategic direction.

View full answer

Is Prestige Consumer Healthcare, Inc. technically bullish or bearish?

20-Sep-2025

As of July 31, 2025, Prestige Consumer Healthcare, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 with a year-to-date return of -17.92% compared to the S&P 500's 12.22%.

View full answer

Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Prestige Consumer Healthcare, Inc. is considered overvalued with a shift in valuation grade from very attractive to attractive, reflected by high P/E, Price to Book, and EV to EBITDA ratios compared to peers, alongside a year-to-date return of -20.49% versus the S&P 500's 13.30% gain.

View full answer

Compare Prestige Consumer Healthcare, Inc. with Similar Stocks

Bausch Health Cos., Inc.MoonLake Immunotherapeutics Amicus Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 3.13% and Operating profit at 3.08% over the last 5 years

Flat results in Jun 25

With ROCE of 12.76%, it has a fair valuation with a 1.99 Enterprise value to Capital Employed

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3,581 Million (Small Cap)

P/E

15.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.54

Return on Equity

10.66%

Price to Book

1.96

Revenue and Profits:

Net Sales:

283 Million

(Quarterly Results - Dec 2025)

Net Profit:

47 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

10.44%

6 Months

0.29%

1 Year

-25.63%

2 Years

-10.18%

3 Years

12.36%

4 Years

17.29%

5 Years

44.01%

Prestige Consumer Healthcare, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.90%

EBIT Growth (5y)

2.19%

EBIT to Interest (avg)

5.29

Debt to EBITDA (avg)

3.40

Net Debt to Equity (avg)

0.49

Sales to Capital Employed (avg)

0.40

Tax Ratio

24.49%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

11.87%

ROE (avg)

14.20%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.79

EV to EBIT

11.98

EV to EBITDA

11.04

EV to Capital Employed

1.54

EV to Sales

3.73

PEG Ratio

1.71

Dividend Yield

ROCE (Latest)

12.84%

ROE (Latest)

11.94%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 88 Schemes (60.18%)

Foreign Institutions

Held by 118 Foreign Institutions (9.47%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 3.39% vs 9.86% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 10.66% vs -11.16% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "283.40",
          "val2": "274.10",
          "chgp": "3.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "90.10",
          "val2": "87.30",
          "chgp": "3.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "10.70",
          "val2": "10.00",
          "chgp": "7.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "46.70",
          "val2": "42.20",
          "chgp": "10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "291.00%",
          "val2": "290.60%",
          "chgp": "0.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 1.10% vs -0.20% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 2.53% vs 354.31% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,137.80",
          "val2": "1,125.40",
          "chgp": "1.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "379.40",
          "val2": "373.10",
          "chgp": "1.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "47.60",
          "val2": "67.20",
          "chgp": "-29.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-12.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "214.60",
          "val2": "209.30",
          "chgp": "2.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "307.00%",
          "val2": "304.30%",
          "chgp": "0.27%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

283.40

274.10

3.39%

Operating Profit (PBDIT) excl Other Income

90.10

87.30

3.21%

Interest

10.70

10.00

7.00%

Exceptional Items

0.00

Consolidate Net Profit

46.70

42.20

10.66%

Operating Profit Margin (Excl OI)

291.00%

290.60%

0.04%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 3.39% vs 9.86% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 10.66% vs -11.16% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

1,137.80

1,125.40

1.10%

Operating Profit (PBDIT) excl Other Income

379.40

373.10

1.69%

Interest

47.60

67.20

-29.17%

Exceptional Items

-12.50

0.00

Consolidate Net Profit

214.60

209.30

2.53%

Operating Profit Margin (Excl OI)

307.00%

304.30%

0.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 1.10% vs -0.20% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 2.53% vs 354.31% in Mar 2024

All Annual Results

Company CV

About Prestige Consumer Healthcare, Inc.

Prestige Consumer Healthcare, Inc.

Pharmaceuticals & Biotechnology

Prestige Consumer Healthcare Inc., formerly Prestige Brands Holdings, Inc. is engaged in the marketing, sales and distribution of over-the-counter healthcare products. The Company operates through two segments: North American Over-the-Counter (OTC) Healthcare, and International Over-the-Counter Healthcare. Its portfolio of OTC healthcare products includes core brands, such as DenTek specialty oral care products, Monistat women's health products, Nix lice treatment, Chloraseptic sore throat treatments, Clear Eyes eye care products, Compound W wart treatments, The Doctor's NightGuard dental protector, Little Remedies pediatric over-the-counter products, Efferdent denture care products, Luden's throat drops, Dramamine motion sickness treatment, BC and Goody's pain relievers, Beano gas prevention, Debrox earwax remover, and Gaviscon antacid.

Company Coordinates

Company Details

660 White Plains Rd , TARRYTOWN NY : 10591-5139

Tel: 1 914 5246800

http://prestigebrands.com

Registrar Details